SOURCE: EBS Technologies GmbH
November 16, 2015 05:00 ET
EBS Therapy: Innovative Stimulation Method Enables Non-Invasive Treatment of Visual Field Loss
New Clinical Trial Data Presented at the NSUKI Congress in London
HENNIGSDORF, GERMANY–(Marketwired – Nov 16, 2015) – Damage to the optic nerve, caused by glaucoma, circulatory disorder, trauma or stroke is a frequent indication. 70 million people alone are affected by glaucoma worldwide.1 The related degeneration of cells in the eye often leads to visual field loss with symptoms such as blurred sight, black and bright spots or other limitations of the visual field. So far, the therapy options for visual field loss were very limited. Now, clinical trial results for the non-invasive EBS Therapy indicate that stimulation of the nerve cells by means of gentle electrical current pulses can help recover lost eyesight.2
Significantly improved visual field
The randomized controlled trial included 98 patients with optic neuropathy that were allocated to two groups. The first group (n=51) was treated with EBS Therapy, the second group (n=47) received a placebo treatment. The trial showed that patients treated with EBS Therapy benefited from a significantly improved visual field compared to the control group. The results of the clinical trial were presented at the annual congress of the Neuromodulation Society of UK and Ireland (NSUKI) in London by Prof. Dr. med. Jens Ellrich, University Aalborg, Denmark, and University Erlangen, Germany: “EBS Therapy has a strong potential. This is not only evident when looking at the clinical data, but also when looking at the growing number of optic nerve disorders occurring in our aging society.”
Two-fold effect of stimulation with current pulses
The mode of action of EBS Therapy: The nerve cells of the retina are stimulated by means of gentle electrical current pulses. Also known as transorbital optic nerve stimulation (tONS), the method has a two-fold effect: targeted rhythmic electrical current pulses stimulate the metabolism of nerve cells, prevent the further degeneration of cells in the retina (neuroprotection) and support the regeneration (neuroregeneration) of nerve tissue.
“In Germany, we have already successfully treated many patients that did not benefit from traditional therapy options. The presentation of our convincing clinical trial results at the NSUKI congress to an international audience builds the perfect basis for our further expansion in the growing global market for neuromodulation,” says Ulf Pommerening, CEO of EBS Technologies.
1. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review.
2. Ellrich, J., Pommerening, U., and Wundrich, I. Transorbital neurostimulation improves vision in patients with optic neuropathies. ClinicalTrials.gov Identifier: NCT01280877, 2015.
About EBS Technologies
EBS Technologies GmbH, based in Hennigsdorf close to Berlin, Germany, develops software and hardware for medical stimulation therapies. The company holds several patents in the EU and the USA, and has successfully completed a clinical trial of the EBS therapy. The EBS therapy system is approved for the treatment of visual field loss in accordance with EU regulations as a medical device with a CE label. For more information on EBS Technologies, please visit: www.ebstech.eu
More information on the EBS therapy and a complete list of therapy centers is available under www.ebs-therapy.com
Eva Birle / Christine Bahren
Tel: +49 089 13 95 78 27 11 /17
Email: birle / baehren
Filed under: #!!# |